



1981 - 2026
Forty-Five Years
of Education in Cancer Care

www.eso.net

OUR VISION

To ensure that all cancer patients have access to unbiased and evidence-based competent care from adequately trained health professionals.


OUR MISSION

The European School of Oncology is an independently funded non-profit organisation dedicated to quality education and training, because we believe all patients deserve equal access to competent cancer care.

EDUCATIONAL PATHWAY


ESO offers medical, radiation and surgical oncologists and other health professionals a structured educational pathway that spans their career from medical students through to taking on leadership responsibilities.

ESO EDUCATIONAL PATHWAY



A STORY OF VISION AND GENEROSITY

Umberto Veronesi
Founder



The idea of European School of Oncology was originally presented by Umberto Veronesi, an Italian breast surgeon, visionary in cancer care and treatment to the European Society of Surgical Oncology (ESSO) General Assembly in Lousanne on 29 October 1981. With the approval and the endorsment of the Society, the project was developed in all its details and the school was officially established in Milan a year later thanks to the first generous donation of Princess Laudomia Del Drago, a distinguished member of the Roman aristocracy and a breast cancer survivor.

Veronesi and Del Drago were passionate about reducing the number of cancer deaths resulting from a late diagnosis or inadequate treatment. They believed by through increasing access to oncology education, cancer could not just be diagnosed sooner but treatment could improve, and in turn reduce the mortality rates.

Leading oncologists from around Europe joined their cause, playing a key role in the founding of ESO. They include Sir Michael Peckham, Franco Cavalli, Louis Denis, and Bob Pinedo.

45 years on, we are continuing their initial passion by providing oncology education that helps improve the treatment of cancer patients. Through our extensive learning programmes, we're reaching areas where education is most needed, both geographically and scientifically.

CO-FOUNDERS



Michael Peckham



Louis Denis



Franco Cavalli



Bob Pinedo



Laudomia Del Drago
Co-founder



THE BOARD
OF DIRECTORS

Fedele Gubitosi

ESO President

Members

Marco Alloisio Milan

Alberto Azario Milan

Piergiuseppe Biandrino Milan

Donella Bossi Pucci Rome

Roberto Camilli Milan

Alberto Costa Milan

Vincenzo Finizzola Milan

Thomas Galdy Florence

Laura Pellegrini Rome

Lorenza Wyder Zollikon

Auditors

Marco B. Lovati Milan

Barbara Negri Milan

Francesco Porpora Milan

ESO OFFICES



Milan

Via Turati 29, 20121 Milano, Italy



Bellinzona

Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland

OUR FINANCIAL
INDEPENDENCE

Ugo Rock

ESO Honorary President



Umberto Veronesi and Princess Laudomia Del Drago's vision of a School of Oncology inspired by European medical knowledge and tradition was sustained by the generosity of several private donors like Mr Jost Reinhold and Mr Hans Wyder in Milan. The turning point came through the support of the Necchi Campiglio family. Mr Necchi Campiglio was an Italian entrepreneur without children or heirs, whose metastatic prostate cancer was misdiagnosed as arthritis. The family decided that the sole heir of their patrimony would be ESO, guaranteeing its permanent financial stability and unique scientific independence.

This independence has given ESO the great privilege of being able to think freely and act freely in a world full of constraints and boundaries.

ESO's activities continue to be exclusively supported by private donations and EU grants.



Villa Necchi Campiglio in Milan, Italy.



THE FFO FOUNDATION

Antonello Perricone

FFO President

The Fondazione per la Formazione Oncologica (FFO) was established in 1986 thanks to the generous support of private donors to ensure financial stability to ESO.

The main purpose of the FFO, whose headquarters are in Milan, is the financial sustainability of ESO's activities. The Foundation, as well as the School, was conceived after a dramatic finding - according to the American Medical Association, that up to an estimated 20% of all cancer deaths result from delayed diagnosis or inadequate treatment. In other words, one in five people could be saved by applying knowledge and resources.

The Foundation is recognized of a public interest by the Lombardy Region and donations are tax deductible.

FFO Board of Trustees:

Members

Michelangelo Balmelli *Lugano*
Andrea Cavallari *Rome*
Alberto Costa *Milan*
Paola Favati *Milan*
Luca Gianni *Milan*
Fedele Gubitosi *Milan*
Pietro Presti *Turin*
Ugo Rock *Milan*
Gianluca Vago *Milan*
Gualtiero Ventura *Rome*

Auditors

Antonio Ortolani *Milan*
Uberto Barigozzi *Milan*
Eleonora Spagnuolo *Milan*



THE ESO FOUNDATION

Carlo Maggini

ESOF President



The ESO Foundation was established in 1988 thanks to the legacies of Mrs. Gigina and Nedda Necchi to support and implement the project conceived in 1981 by Professor Umberto Veronesi and Princess Laudomia Del Drago. The Foundation's mandate is to secure resources that enable the School to develop initiatives that increase the skills of health professionals in the field of oncology, to support training projects and to accelerate the transfer of scientific advances to clinical practice.

ESOF is based in Lugano and is governed by a Board of Trustees.

ESOF and FFO annually assess ESO's activities and initiatives, support their implementation and monitor their effectiveness.

ESOF Board of Trustees:

Michele Passardi *Bellinzona* - Executive Adviser

Members

Michelangelo Balmelli *Lugano*
Fabrizio Barazzoni *Lugano*
Franco Cavalli *Bellinzona*
Maria Cristina Cedrini *Lugano*
Alberto Costa *Milan*
Silke Gillesen Sommer *Bellinzona*
Fedele Gubitosi *Milan*
Carlo Marazza *Lugano*
Glaucio Martinetti *Bellinzona*
Alessandro Rusconi *Lugano*
Laura Sadis *Lugano*
Lorenza Wyder *Zollikon*





STRATEGIC GOALS

European School of Oncology
Strategic plan 2026-2028



The Open University

GOAL 1 Distance Learning in Partnership

As part of its new strategic plan, ESO has decided to reorganize and relaunch its online educational offering under the name **ESO Distance Learning (ESO DL)**, fully integrated into the School's website. This marks a transition from the previous e-ESO platform to a more structured and recognizable model, designed to deliver high-quality content with improved accessibility to its global audience.

Additionally, materials from the e-ESO platform will be reviewed and curated to develop a pilot course which ESO aims to produce in collaboration with the renowned distance learning provider, Open University. The decision to seek an external partner stems from the recognition that distance learning requires specific methodological expertise and technologies that ESO currently does not possess and does not intend

to develop internally at this time. Therefore, ESO has chosen to initiate a collaboration with the **Open University (OU)**, with whom it has successfully worked in the past and who is also interested in expanding into the field of medical education.


Founded in 1969, the Open University has pioneered distance learning for over 50 years to students across the UK and the world. It is one of the largest universities in Europe with almost 200,000 students and has its headquarters at Walton Hall in Milton Keynes, UK.

The collaboration will begin with the creation of a **pilot course** using selected materials from the e-ESO platform and developed with methodological support from the OU. This course will be the first step toward a new, more structured and accredited online educational offering

GOAL 2 Accreditation and Certification of our educational activities

ESO aims to strengthen its position as a leading oncology education provider by obtaining formal accreditation, enabling it to award academic or continuing medical education (CME) credits for its courses. By clearly defining course content, learning outcomes, and assessment criteria, ESO will enhance the transparency, credibility, and value of its offerings further solidifying its role in providing high-quality, recognized oncology education and

providing oncology professionals with tangible career benefits. ESO will expand its collaboration with universities across Europe to develop a range of Postgraduate programmes. Additionally, ESO will explore the requirements for upgrading its Certificates of Advanced Studies into fully recognized Master's programmes, ensuring greater academic recognition and career advancement opportunities for participants.



GOAL 3 Modernize and Humanize oncology education

ESO will strengthen its educational pathway by embedding ad hoc sessions on essential and effective skills for the clinic throughout all Pathway events, reflecting ESO's belief that such skills constitute an integral part of medical education. Additionally, ESO will incorporate digitalization, AI, and interactive learning activities into its educational programmes

while maintaining a holistic patient-centred approach. This includes exploring AI applications in imaging and diagnostics, utilizing digital and simulation-based teaching methods, expanding European collaboration in clinical education, and developing specialized educational tools for non-clinical oncology researchers to foster cross-disciplinary collaboration.

GOAL 4 ESO College and multidisciplinary

ESO College will continue to establish itself as a leading **multidisciplinary and multiprofessional network** dedicated to education, career development, and collaboration among oncology professionals. Through its elected Council and dedicated working groups in **education, membership, career development, and strategy**, the College will strengthen its internal community, deepen its connection with ESO, and expand its

strategic influence in the oncology field. The College will also serve as a talent pool, identifying and nurturing the next generation of oncology leaders and educators. In line with its mission to promote a multidisciplinary approach to oncology, ESO plans to further develop this vision in collaboration with OncoDaily, a media partner that shares ESO's values and commitment to innovation.

MANAGING ESO

Rossella Blasi

Executive Director



Since January 2023, Rossella Blasi, a senior manager with extensive experience in human resources and finance, has joined the General Management as Director General, supporting the CEO in governance and strategic development activities.

With over twenty years of experience in the management and development of non-profit organizations, Rossella brings an integrated, results-oriented vision, with a strong focus on optimizing human and financial resources as key drivers of sustainable growth.

In her role as Executive Director, she has led a process of organizational evolution within the School, strengthening its position in oncology training through the implementation of strategies aimed at improving processes, enhancing project impact, and ensuring measurable results.

Her contribution has translated into a significant internal reorganization, a strategic review of key partnerships, and the launch of a process to redefine internal competencies, with the objective of strengthening the School's service offering. In this context, she has also promoted the adoption and achievement of ISO 9001 certification, ensuring high-quality standards and a structured approach to continuous improvement.

Within this framework of renewal and innovation, she has also supported the reopening of the historic Venetian venue on San Servolo Island, as a distinctive element for the School's future development.



Island of San Servolo in Venice.
One of the best known ESO locations.

MANAGING ESO

Alberto Costa

Chief Executive Officer



Dr Alberto Costa, a breast cancer surgeon from Milan with previous research activity in the field of cancer chemoprevention, was appointed ESO's Director in 1982. He took on the task of establishing the School, its offices and its first activities and has managed ESO ever since.

For over 40 years, Dr Costa designed ESO's annual programme of activities whilst reporting to the Board of Directors and the Scientific Committee. In 2017 the Board confirmed his position as CEO. He is responsible for the scientific content of ESO's activities.

He was editor in chief of the journal *The Breast* from 2003 to 2015 and a member of the editorial board of *Nature Reviews Clinical Oncology*. He has also been the Editor, from 2015 to 2019, of the ESO magazine, *CancerWorld*.

Co-founder of ABC, Advanced Breast Cancer conference, Europa Donna, the European Breast Cancer Coalition, he also founded Europa Uomo, the patient advocacy movement on prostate cancer. He has served as Secretary General of the European Organisation for the Research and Treatment of Cancer (EORTC) and the Federation of European Cancer Societies (FECS), both in Brussels. He actively contributed to the establishment and development of the American Italian Cancer Foundation (AICF) in New York, of which is member of the Advisory Board.

From 2021 to 2025, he served as adviser of the EU Commissioner for Health, Mrs Stella Kyriakides, for cancer policy.



Villa Verganti Veronesi, in the countryside near Milan



THE ADVISORY BOARD

CHAIR

Stella Kyriakydes



Stella Kyriakides is a prominent Cypriot politician and health advocate who served as the European Commissioner for Health and Food Safety from December 2019 to November 2024. Prior to this role, she was a member of the Cyprus House of Representatives from 2006 to 2019. In 2017, she made history by becoming the first Cypriot and the fourth woman to be President of the Parliamentary Assembly of the Council of Europe.

Kyriakides has held several leadership positions, including President of the Human Rights Committee and Vice President of the Health Committee in the Cyprus Parliament. She also chaired the Health and Social Affairs Committee of the Parliamentary Assembly and led the European Breast Cancer Coalition Europa Donna. A strong advocate for patient rights, Kyriakides founded Europa Donna, Cyprus' first breast cancer association, and served as its president for 15 years. She also worked in the Cyprus Mental Health services as a psychologist, focusing on child and adolescent mental health. For her significant contributions to the field of health, Stella Kyriakides was awarded an honorary Doctor of Science degree from the University of Reading.

HONORARY CHAIR

Nicholas Pavlidis

After many years ESO decided to replace the Scientific Committee with an Advisory Board including representatives of the civil society, universities and experts in communication, artificial intelligence (AI) and health economics.

Prof. Nicholas Pavlidis served as Senior Oncologist at the Cancer Institute in Athens before moving to the University of Ioannina where he was elected as Professor of Medical Oncology and held the position of Head of the Department of Medical Oncology at Ioannina University Hospital from 1988 to 2016.

Since 1989, Prof. Pavlidis has served the European School of Oncology as the Chair of Eastern European and Balkan activities, member of the Scientific Committee, Masterclass Coordinator and he is currently the Chair of the Advisory Board. Among his research activities, cancer of unknown primary and cancer during pregnancy were the two topics where he mainly dedicated his scientific interest for many years.

Members

Luca Bertolaccini Italy

Marta Bertolaso Italy

Lesley Fallowfield United Kingdom

Lucas Gambardella Switzerland

Silke Gillissen Sommer Switzerland

Stella Kyriakides Cyprus **Chair**

Mark Lawler United Kingdom

Simon Oberst Belgium

Nicholas Pavlidis Greece **Honorary Chair**

Cristiana Sessa Switzerland

Richard Sullivan United Kingdom

Luzia Travado Portugal

Eric Van Cusem Belgium



SCIENTIFIC PROGRAMME COMMITTEE

The Multidisciplinary Scientific Council (MSC) is a group of highly experienced professionals, carefully selected by ESO, tasked with providing transparent monitoring and evaluation of the scientific content of the School's activities. The MSC not only reviews and approves teaching subjects and speakers based on their expertise, but also ensures balanced representation in terms of gender, geographic diversity, and multidisciplinary perspectives.

This approach guarantees that our programmes not only meet the highest scientific standards but also reflect a broad, inclusive, and European perspective.



Alessandra Curioni Fontecedro

**MEDICAL
ONCOLOGY**

Prof. Alessandra Curioni Fontecedro was appointed Full Professor of Oncology at the University of Fribourg in 2022 and works as Head of Oncology at the Cantonal Hospital HFR Fribourg, Switzerland. She is Vice-President of the Immuno-Oncology Group of the Swiss Group for Clinical Cancer Research (SAKK), as well as a faculty member of the Immuno-Oncology and Immunotherapy Group at ESMO.



Nicola Fusco

PATHOLOGY

Prof. Nicola Fusco is the Director of the Division of Pathology at the European Institute of Oncology (IEO) and Associate Professor of Pathological Anatomy at the Department of Oncology and Haemato-Oncology of the University of Milan. In addition, he directs the institutional Biobank at the IEO and actively participates in an international network of experts in predictive oncological pathology.



Barbara Jereczek Fossa

**RADIATION
ONCOLOGY**

Prof. Barbara Jereczek Fossa is a Full Professor of Radiation Oncology at the University of Milan and Chair of the Radiation Oncology Department at the European Institute of Oncology (IEO), Milan, Italy. She is President Elect of the European Society of Radiotherapy and Oncology (ESTRO) and actively contributes to various scientific societies, committees, and editorial boards.



Riccardo Audisio


**SURGICAL
ONCOLOGY**

Prof. Riccardo Audisio is Professor at the Institute of Clinical Sciences, University of Göteborg, Sweden and is Editor-in-Chief of the European Journal of Surgical Oncology (EJCO). He is Past-President of the European Society of Surgical Oncology (ESSO) and member of several international scientific societies including BASO, SSO, AAA, SIOG and EUSOMA.



ORGANIZATION CHART

As of June 2026



THE COLLEGE OF THE EUROPEAN SCHOOL OF ONCOLOGY

The College of the European School of Oncology (ESO College) is a community designed to support the ESO Educational Pathway and guide participants throughout their oncology careers. Open to those selected for ESO’s educational programmes, the College offers structured support to help members deepen their knowledge, expand their network, and pursue meaningful milestones in cancer education.

The ESO College Council is a group of members elected by their peers to represent the College community and contribute to the development of its activities and strategy. The Council plays a key role in shaping governance, identifying new initiatives, supporting member engagement, and strengthening networking opportunities across the College.

Through its work, the Council leads targeted Working Groups focused on key areas such as strategy, education, career development, and membership, ensuring that ESO College remains dynamic, responsive, and aligned with the needs of its members. The term of office on the College Council lasts 2 years. Elections will be held in the second half of 2026 for the next mandate: Jan 2027 – Dec 2028.

ESO COLLEGE COUNCIL MEMBERS

 Eduard Alexandru Bonci Breast Unit Champalimaud Research and Clinical Centre, Lisbon	 Justyna Bochenek-cibor Radiation Therapy Dept. St' Lukas Hospital, Tarnów	 Lazaros Papadopoulos Breast Unit Dept. IASO Gynecological Clinic, Athens	 Milos Grujic Radiation Oncology Dept. University Clinical Center Kragujevac, Kragujevac
 Mohamed Emam Sobeih Medical Oncology Dept. National Cancer Institute Cairo, Nasr City	 Panagiotis Vlachostergios Medical Oncology Dpt. Iaso Thessalias General Hospital, Larissa	 Silvia Brotea-mosoii Medical Oncology Dept. Oncology Institute of Bucharest, Bucharest	 Simona Volovat Oncology Dept. Institute of Regional Oncology Iasi, Iasi



DOMIETTA DEL DRAGO FELLOWSHIP FUND

Donella Bossi Pucci

The two founders of the European School of Oncology were Professor Umberto Veronesi, the visionary surgeon who had just published his seminal paper on conservative surgery for breast cancer in the New England Journal of Medicine, and Princess Laudomia (Domietta) Del Drago, distinguished member of the Roman aristocracy and a breast cancer survivor. Veronesi had the original idea of a school of oncology for Europeans inspired by European medical knowledge and tradition. He became the first chair of the School's Scientific Committee.


Del Drago gave the School its first donation (first of a long series!) and became President of the School's Board of Directors. She continued to support ESO throughout her life and when she passed away in 2019 she asked her daughter, Donella, to ensure their family continued its financial commitment to the European School of Oncology, together with our private European donors.

The Domietta Del Drago fellowship fund was established in January 2020 in her memory and has the scope of providing financial aid to doctors and nurses who have successfully passed the selection process for one of ESO's educational programmes, but have difficulties in covering their participation costs.



Silvio Monfardini

Chair



The European ONCOpedia (www.oncopediawiki.org) is a European School of Oncology project to document the history of Europe's contributions to improving cancer care. It aims to give insights into how those contributions came about, and what difference they made to patients, by hearing where possible, directly from the people who were involved.

The European School of Oncology chose to focus the ONCOpedia on European contributions, because this is our core community and we want to tell our own story. However, we are also keen to acknowledge instances where the contributions covered include important input from the US or elsewhere.

Editorial Committee:

Chair: Silvio Monfardini

Editorial Director: Bernardino Fantini

Editorial coordinator: Anna Wagstaff

Committee members:

Adriana Albini, Riccardo Audisio,
Mariano Barbacid, Alessandro Blasimme,
Giovanni Boniolo, Bettina Borisch,
Alberto Cambrosio, Steven Pavletic, Philip
Poortmans, Paolo Vineis and Theo Wagener



THE ESO OFFICIAL JOURNAL

Christian Rolfo



The School's official journal is *Critical Reviews in Oncology/Hematology* (CROH), whose editor-in chief is Dr. Christian Rolfo (New York). CROH publishes scholarly, critical reviews in all fields of oncology and hematology, as well as reviews and original research articles in the field of geriatric oncology. The journal also facilitates the diffusion of ESO articles.



COORDINATORS OF THE POSTGRADUATE PROGRAMMES



BREAST CANCER

Matteo Lambertini

From the very beginning, ESO has devoted special attention to breast cancer, the most common cancer in women worldwide. Our founder Umberto Veronesi dedicated much of his career towards breast cancer research and it is also the specialty research field of our CEO, Alberto Costa.

The **Certificate of Competence in Breast Cancer (CCB)** was launched in 2015 and is the first competence programme to focus on the improvement of both the clinical and the scientific capability of oncologists, ensuring better-quality management of breast cancer patients.

The CCB programme is held in collaboration with Ulm University, Ulm, Germany.



GASTROINTESTINAL CANCERS

Sara De Dosso

Gastrointestinal cancers represent almost 1/4 of all cancers diagnosed in adults and include colorectal cancer, stomach cancer, pancreatic cancer and liver cancer.

The **Certificate of Advanced Studies in Gastrointestinal Cancer (CAS-GI)** is the first competence programme to focus on the improvement of both the clinical and scientific capability of oncologists, ensuring better-quality management of patients with gastrointestinal cancers.

The CAS-GI programme is held in collaboration with the Università della Svizzera italiana (USI), Lugano, Switzerland. The second cohort started in June 2024 and will end in November 2025.

GYNAECOLOGICAL CANCERS

Ilaria Colombo



The first edition of the **Certificate of Advanced Studies in Gynaecological Cancers (CAS-Gyn)** was launched in 2023 and is the first competence programme to focus on advancing the knowledge and science in the management of patients affected by gynaecological cancers.

The CAS-Gyn programme is held in collaboration with the Università della Svizzera italiana (USI), Lugano, Switzerland.

The first cohort started in August 2023 and ended in January 2025.

The second cohort will begin in June 2025 and will end in late 2026.

LYMPHOMA

Emanuele Zucca



The **Certificate of Competence in Lymphoma (CCL)** was launched in 2013 and is the first competence programme to focus on the improvement of both the clinical and the scientific capability of oncologists, ensuring better-quality management of lymphoma patients.

The CAS LYM programme is held in collaboration with the Università della Svizzera italiana (USI), Lugano, Switzerland. The next cohort will start in June 2025 and will conclude in early 2027.



PROSTATE CANCER

Ursula Vogl

The decision to prioritize prostate cancer research was taken to honor the memory of a major donor to the School who passed away due to the disease. This choice also acknowledges the need to focus on relatively under-researched areas within prostate cancer care: active surveillance and the study of predictive and prognostic factors.

The **Certificate of Advanced Studies in Prostate Cancer (CAS-Pr)** is a postgraduate programme focused on the improvement of both the clinical and scientific capability of oncologists, aiming to ensure better-quality management of patients with prostate cancer. The CAS-Pr programme is held in collaboration with the Università della Svizzera italiana (USI), Lugano, Switzerland.

The second cohort will start in September 2025 and will end in late 2026.



THORACIC MALIGNANCIES

Alessandra Curioni Fontecedro

The **Certificate of Advanced Studies in Thoracic Malignancies (CAS-TM)** was launched in 2025 and the programme will focus on the improvement on both the clinical and the scientific aspects of improving quality in the management of patients with lung cancer and other thoracic malignancies.

The CAS-TM programme is held in collaboration with the University of Fribourg, Switzerland. The first cohort started in March 2025 and will end in June 2026.

Alessandra Curioni Fontecedro, who previously served as Deputy Director Lung and Thorax Cancer Centre at the University Hospital Zurich, was appointed Full Professor of Oncology at the University of Fribourg and Director of Oncology at the Hospital of Fribourg, Switzerland in 2022 and serves as the ESO Advisor and Chair of the CAS-TM programme.



EU PROJECTS

ESO is involved in different European Projects either alone or with other oncology stakeholders. Here is a brief summary of the main ongoing activities and future plans.

INTERACT-EUROPE 100

Programme: EU4Health



The INTERACT-EUROPE 100 project aims at implementing the Inter-specialty Cancer Training (ISCT) curriculum developed under the INTERACT-EUROPE project. The objective of the ISCT programme is to foster a patient-centric approach to quality cancer care through the promotion of multidisciplinary and multi-professional teams working across Europe.

The project is co-funded by the EU under the EU4Health programme 2021-2027 as part of Europe's Beating Cancer Plan, it is coordinated by ECO and ESO is the leader of Work Package 3 on the delivery of the ISCT programme by overseeing the training of trainers (experts in the fields of clinical oncology, surgery, radiation oncology, cancer nursing and other specialised staff from at least 100 cancer centres in Europe) and subsequently that of trainees.

INTERACT2 is a 36-month project (December 2023 – November 2026).

EU PAST PROJECTS



**INTERACT
EUROPE**




Erasmus+





ESO BOUNDARIES:
A SPECIFIC MISSION

ESO's activities are predominately held in Europe, but access to them is broadly European. This includes non EU countries extending east towards Eurasia, as well as regions closely connected to European culture and languages, and south to include all Mediterranean countries.



Countries
that can
currently host
our events:

highlighted to show
where we organise
in-person courses
and activities.

ESO AMBASSADORS

Lejla **Alidzanovic Nurkanovic**, BA
Elvina **Almuradova**, TR
Mikayel **Arustamyan**, AM
Justyna **Bochenek-Cibor**, PL
Simona **Borilova**, CZ
Silvia **Brotea-Mosoiu**, RO
Rita **Canario**, PT
Bruna **David**, BR
Milos **Grujic**, RS
Alisher **Kahharov**, UZ
Assia **Konsoulova**, BG
Fatjona **Kraja**, AL
Alvin **Lee**, GB
Vadim **Lesan**, DE
Elene **Mariamidze**, GE
Leyla **Mehmetbeyli**, AZ
Omnia **Mohamed**, EG
Loredana **Mrak**, SI

Elena **Napolskaia**, RU
Zsuzsanna **Orosz**, HU
Lazaros **Papadopoulos**, GR
Gordana **Petkovska**, MK
Olena **Postupalenko**, UA
Brunilda **Profka Haxhiu**, XK
Marina **Puchinskaya**, BY
Ina **Suppan**, AT
Narmin **Talibova**, DE
Ana **Tecic Vuger**, HR
Eugeniu **Valic**, MD
Nataliia **Verovkina**, UA/US
Simona **Volovat**, RO



2026
ESO TEAM



Rossella Blasi
Executive Director



Alessandra Antenucci
Accounting



Alice Ciocchini
Event Manager



Mariachiara Deleo
Communication Coordinator



Anna De Vita
Content Creator



Elena Fiore
Event Manager



Corinne Hall
ESO College Manager



Dolores Knupfer
Event Manager



Gabriele Maggini
Bellinzona Office Manager
and ONCOpedia



Sarah Jane Ortelli Giannakis
Event Manager



Alexandra Zampetti
Event Manager



Fausta Amati
Administration



Michele Guerrieri
Legal Adviser



Michele Passardi
ESOF - Executive Adviser



Lorenzo Pini
IT Manager

COLLABORATORS



European School
of Oncology

CONTACT US

MILAN OFFICE

Via Turati 29
20121 Milano,
Italy

BELLINZONA OFFICE

Via Vincenzo Vela 6
6500 Bellinzona,
Switzerland

eso@eso.net
www.eso.net



@ESONcology



European School
of Oncology

